Real-world experience on off-label use of imiquimod 5% as an adjuvant therapy after surgery or as a monotherapy for lentigo maligna
Articolo
Data di Pubblicazione:
2021
Citazione:
Real-world experience on off-label use of imiquimod 5% as an adjuvant therapy after surgery or as a monotherapy for lentigo maligna / Lallas, A; Moscarella, E; Kittler, H; Longo, C; Thomas, L; Zalaudek, I; Kyrgidis, A; Manoli, S M; Di Meo, N; Papageorgiou, C; Apalla, Z; Argenziano, G. - In: BRITISH JOURNAL OF DERMATOLOGY. - ISSN 0007-0963. - 185:3(2021), pp. 675-677. [10.1111/bjd.20407]
Abstract:
Because of the tendency of lentigo maligna (LM) for subclinical extension, staged excisions with margin control achieve lower recurrence rates than conventional wide local excision (0-9.5% vs 8-20%). However, these surgical techniques are limited by their requirement in time, costs and training.
Tipologia CRIS:
Articolo su rivista
Elenco autori:
Lallas, A; Moscarella, E; Kittler, H; Longo, C; Thomas, L; Zalaudek, I; Kyrgidis, A; Manoli, S M; Di Meo, N; Papageorgiou, C; Apalla, Z; Argenziano, G
Link alla scheda completa:
Pubblicato in: